Toggle light / dark theme

Researchers from North Carolina State University, the University of North Carolina at Chapel Hill and First Affiliated Hospital of Zhengzhou University have developed a synthetic version of a cardiac stem cell. These synthetic stem cells offer therapeutic benefits comparable to those from natural stem cells and could reduce some of the risks associated with stem cell therapies. Additionally, these cells have better preservation stability and the technology is generalizable to other types of stem cells.

Stem cell therapies work by promoting endogenous repair; that is, they aid damaged tissue in repairing itself by secreting “paracrine factors,” including proteins and genetic materials. While stem cell therapies can be effective, they are also associated with some risks of both tumor growth and immune rejection. Also, the cells themselves are very fragile, requiring careful storage and a multi-step process of typing and characterization before they can be used.

Ke Cheng, associate professor of molecular biomedical sciences at NC State, associate professor in the joint biomedical engineering program at NC State and UNC, and adjunct associate professor at the UNC Eshelman School of Pharmacy, led a team in developing the synthetic version of a cardiac stem cell that could be used in off-the-shelf applications.

Read more

The Cellage synthetic biology digest.


The field of synthetic biology holds the potential to treat a variety of aging processes and treat age-related diseases. Synthetic biology allows biologists to create new functions in cells by creating synthetic cellular programs and could allow us to combat age-related diseases in ways never before considered.

#aging #crowdfundthecure

Read more

CRISPR can help us end many diseases and guide evolution and is probably one of the most powerful tools we have recently added to our toolkit.


Imagine you could edit a mouse’s genes to be resistant to Lyme Disease. The mouse would breed and evolution would take its course, leading to the extinction of the disease. That’s the vision for scientists developing CRISPR, technology that allows scientists to rewrite the code of life. William Brangham talks to Michael Specter who wrote about CRISPR for The New Yorker.

Read more

Nice.


Synthetic RNA kit business Synthego has raised $41 million to step up its efforts to make CRISPR gene editing easier and more accurate. The West Coast startup relied heavily on tech VCs for the cash, but also gained validation from having CRISPR pioneer Jennifer Doudna invest in its business.

Redwood City, CA-based Synthego exited stealth in August, four years after it was set up by two former SpaceX computer engineers. In those early years, which were bankrolled by an $8.3 million investment in 2013, Synthego established an automated manufacturing process for guide RNA products that it thinks sets it apart from larger competitors in terms of cost, turnaround time and editing efficiency.

Sythengo has persuaded some big names it is on to something. 8VC, an infrastructure-focused VC that also invested in uBiome, led the round with support from fellow new backers AME Cloud Ventures, Elements Capital, OS Fund, Alexandria Equities and ZhenFund. Existing investors including Peter Thiel’s Founders Fund and Menlo Ventures also contributed to the Series B round.

Read more

In Brief CRISPR has opened up limitless avenues for genetic modification. From disease prevention to invasive species control, Jennifer Kahn discusses the discover, application, and implications of gene drives.

Jennifer Kahn, a science journalist for the New York Times, recently did a TED Talk in which she discussed the discovery, application, and implications of a CRISPR gene drive used to make mosquitoes resistant to malaria and other diseases like chikungunya, and Zika.

Watch the talk in the video below, and learn how geneticists are achieving the (seemingly) impossible:

Read more

Paleontologist Jack Horner participates in a “Jurassic World” Q&A at the Natural History Museum.

Here at Popular Science, we can’t wait to see Jurassic World, which opens in theaters nationwide today. I mean, who can resist velociraptor biker gangs:

But we were also curious about the real scientific research that inspired the movie. So we talked with Jack Horner, a noted paleontologist who has consulted on the entire Jurassic Park movie franchise, including Jurassic World.

Read more